[Systemic Al-amyloidosis. Clinical course and limits of melphalan therapy].
BACKGROUND
Despite significant effects of melphalan and prednisone in the therapy of systemic AL-amyloidosis, overall prognosis is poor and remission of clinical symptoms cannot generally be expected. The course of the disease and results of therapy are possibly influenced by the degree and distribution of organ manifestation at the time of diagnosis. We report a group of patients with renal involvement as the main manifestation of disease.


METHODS
Fifteen patients with systemic Al-amyloidosis without symptomatic myeloma (4 women, 11 men, median age 61 [34 to 71] years) have been attended to at our department and were treated throughout the course of the disease.


RESULTS
Since primary symptoms were frequently unspecific, the maximum time to diagnosis came to 28 months. Renal involvement was primarily evident at the time of diagnosis when all patients manifested proteinuria or renal insufficiency. Ten patients were treated with a melphalan and prednisone containing chemotherapeutic protocol. A significant clinical improvement was observed in no case. One patient in an advanced stage of disease died after the administration of a high-dose regimen of melphalan with blood stem-cell support subsequent to sepsis.


CONCLUSIONS
We do not see an absolute indication for chemotherapy. The unfavorable prognosis--14 patients died an average of 13 months after diagnosis--requires a particularly careful consideration of potential benefits and possible risks accompanying cytostatic therapy.
Hetzel
G R
GR
Klinik für Nephrologie und Rheumatologie, Medizinische Einrichtungen der Heinrich-Heine-Universität, Düsseldorf. hetzelg@uni-duesseldorf.de
Heering
P
P
Grabensee
B
B
D000328:Adult; D000368:Aged; D000686:Amyloidosis / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D004487:Edema / Q000139:chemically induced; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000139:chemically induced; D008297:Male; D008558:Melphalan / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D010292:Paresthesia / Q000139:chemically induced; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D011379:Prognosis; D011507:Proteinuria / Q000139:chemically induced; D015996:Survival Rate
D008558:Melphalan; D011241:Prednisone